The impact of the COVID-19 pandemic on patients with chronic liver disease: Results from the Global Liver Registry.


Journal

Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860

Informations de publication

Date de publication:
10 2022
Historique:
revised: 09 05 2022
received: 01 02 2022
accepted: 30 05 2022
pubmed: 27 7 2022
medline: 28 9 2022
entrez: 26 7 2022
Statut: ppublish

Résumé

Patients with preexisting chronic liver disease (CLD) may experience a substantial burden from both coronavirus 2019 (COVID-19) infection and pandemic-related life disruption. We assessed the impact of the COVID-19 pandemic on patients with CLD. Patients enrolled in our Global Liver Registry were invited to complete a COVID-19 survey. As of June 2021, 2500 patients (mean age ± SD, 49 ± 13 years; 53% men) from seven countries completed the survey. Of all survey completers, 9.3% had COVID-19. Of these patients, 19% were hospitalized, 13% needed oxygen support, but none required mechanical ventilation. Of all patients including those not infected with COVID-19, 11.3% reported that the pandemic had an impact on their liver disease, with 73% of those reporting delays in follow-up care. The Life Disruption Event Perception questionnaire confirmed worsening in at least one area (food/nutrition, exercise, social life, vocation/education, financial situation, housing, or health care) in 81% and 69% of patients with and without a history of COVID-19, respectively (p = 0.0001). On a self-assessed Likert health score scale (range, 1-10; 10 indicates perfect health), patients with a COVID-19 history scored lower (mean ± SD, 6.7 ± 2.2 vs. 7.4 ± 2.2, respectively; p < 0.0001) despite reporting similar health scores if there was no pandemic (mean ± SD, 8.5 ± 1.4 vs. 8.4 ± 1.6, respectively; p = 0.59). After adjustment for country of enrollment, liver disease etiology and severity, age, sex, body mass index, diabetes, and history of psychiatric comorbidities, COVID-19 was found to be independently associated with lower self-assessed health scores (beta = -0.71 ± 0.14; p < 0.0001). The COVID-19 pandemic resulted in a substantial burden on the daily life of patients with CLD.

Identifiants

pubmed: 35880475
doi: 10.1002/hep4.2048
pmc: PMC9350183
doi:

Substances chimiques

Oxygen S88TT14065

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2860-2866

Informations de copyright

© 2022 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.

Références

Gut. 2020 Mar;69(3):564-568
pubmed: 31366455
J Clin Transl Hepatol. 2020 Jun 28;8(2):0024
pubmed: 32309152
Hepatol Commun. 2021 Jul 21;:
pubmed: 34558853
J Hepatol. 2020 Nov;73(5):1231-1240
pubmed: 32553666
Liver Int. 2020 Oct;40(10):2515-2521
pubmed: 32585065
Hepatol Commun. 2021 Jul;5(7):1138-1150
pubmed: 34533001
Hepatol Commun. 2020 Aug 03;4(12):1751-1757
pubmed: 32838107
Psychol Bull. 2007 Mar;133(2):273-93
pubmed: 17338600
Ann Hepatol. 2021 Sep-Oct;24:100338
pubmed: 33647501
Hepatol Commun. 2022 Oct;6(10):2860-2866
pubmed: 35880475
Clin Mol Hepatol. 2015 Sep;21(3):279-86
pubmed: 26523271
Hepatology. 2020 Nov;72(5):1605-1616
pubmed: 32043613
Hepatol Int. 2020 Sep;14(5):621-637
pubmed: 32710250

Auteurs

Zobair M Younossi (ZM)

Center for Liver Disease, Department of Medicine, Inova Fairfax Medical Campus, Falls Church, Virginia, USA.
Inova Medicine, Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia, USA.

Yusuf Yilmaz (Y)

Department of Gastroenterology, School of Medicine, Marmara University, Istanbul, Turkey.
Liver Research Unit, Institute of Gastroenterology, Marmara University, Istanbul, Turkey.

Mohamed El-Kassas (M)

Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt.

Ajay Duseja (A)

Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Saeed Hamid (S)

Department of Medicine, Aga Khan University, Karachi, Pakistan.

Gamal Esmat (G)

Faculty of Medicine, Cairo University, Cairo, Egypt.

Nahum Méndez-Sánchez (N)

Liver Research Unit, Medica Sur Clinic and Foundation, National Autonomous University of Mexico, Mexico City, Mexico.

Wah Kheong Chan (WK)

Gastroenterology and Hepatology Unit, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.

Ashwani K Singal (AK)

Division of Gastroenterology and Hepatology, University of South Dakota, Sioux Falls, South Dakota, USA.
Avera University Health Center and Transplant Institute, Sioux Falls, South Dakota, USA.

Brian Lam (B)

Center for Liver Disease, Department of Medicine, Inova Fairfax Medical Campus, Falls Church, Virginia, USA.
Inova Medicine, Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia, USA.

Sean Felix (S)

Inova Medicine, Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia, USA.

Elena Younossi (E)

Inova Medicine, Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia, USA.

Manisha Verma (M)

Center for Liver Disease, Department of Medicine, Inova Fairfax Medical Campus, Falls Church, Virginia, USA.
Inova Medicine, Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia, USA.

Jillian K Price (JK)

Inova Medicine, Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia, USA.

Fatema Nader (F)

Center for Outcomes Research in Liver Disease, Washington, District of Columbia, USA.

Issah Younossi (I)

Center for Outcomes Research in Liver Disease, Washington, District of Columbia, USA.

Andrei Racila (A)

Center for Liver Disease, Department of Medicine, Inova Fairfax Medical Campus, Falls Church, Virginia, USA.
Inova Medicine, Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia, USA.
Center for Outcomes Research in Liver Disease, Washington, District of Columbia, USA.

Maria Stepanova (M)

Center for Outcomes Research in Liver Disease, Washington, District of Columbia, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH